ストックスクリーナーアプリを入手
68.99
7.78%
4.98
プレマーケット:
69.00
0.01
+0.01%
Spyre Therapeutics Inc (SYRE) 最新ニュース
Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal - MSN
SYRE Secures $403M Common Stock Offering - GuruFocus
Spyre Therapeutics Announces $403M Public Offering - National Today
SYRE Maintained by Wedbush -- Price Target Raised to $80.00 - GuruFocus
Spyre Therapeutics prices $403M public stock offering at $62 - Investing.com
Spyre Therapeutics announces pricing of upsized $403 million public offering of common stock - marketscreener.com
Spyre Therapeutics Announces $403 Million Public Offering of Common Stock - Quiver Quantitative
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
SYRE Maintained by Wells Fargo -- Price Target Raised to $90 - GuruFocus
SYRE Maintained by Baird -- Price Target Raised to $90.00 - GuruFocus
Spyre Therapeutics launches $300 million stock offering By Investing.com - Investing.com Australia
SYRE Initiated Coverage by Raymond James -- Strong Buy Rating As - GuruFocus
Mizuho Boosts Price Target on Spyre Therapeutics to $84 From $53, Keeps Outperform Rating - Moomoo
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst Upgrade - MarketBeat
SYRE Initiated Coverage by Raymond James -- Strong Buy Rating Assigned - GuruFocus
SYRE Maintained by Deutsche Bank -- Price Target Raised to $88 - GuruFocus
Spyre Therapeutics: Strong SPY001 Data Sets Up A Catalyst-Rich 2026 (NASDAQ:SYRE) - Seeking Alpha
Deutsche Bank Adjusts Spyre Therapeutics PT to $88 From $55, Maintains Buy Rating - marketscreener.com
Spyre Sees Monotherapy Potential For UC Drug After Phase II Data - Citeline News & Insights
Positive Phase 2 Results Boost Spyre Therapeutics (SYRE) - GuruFocus
Spyre Therapeutics, Inc. (SYRE) Files 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative ColitisSlideshow (NASDAQ:SYRE) 2026-04-14 - Seeking Alpha
SYRE Maintains by Jefferies -- Price Target Raised to $85.00 - GuruFocus
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics (SYRE) Launches $300M Public Offering to Fund Treatment Development - GuruFocus
Spyre Therapeutics (SYRE) Boosts Confidence in SPY001 Data - GuruFocus
Raymond James initiates Spyre stock with strong buy rating - Investing.com UK
Spyre (SYRE) Announces Stellar UC Treatment Trial, Hits 4-Year High - Insider Monkey
SYRE Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
Spyre Therapeutics (SYRE) Initiates $300 Million Stock Offering - GuruFocus
Spyre Therapeutics (SYRE) Reveals Promising Results in Ulcerativ - GuruFocus
Spyre Therapeutics stock falls on $300M stock offering - Investing.com
Spyre Therapeutics stock falls on $300M stock offering By Investing.com - Investing.com Canada
Spyre Therapeutics (NASDAQ: SYRE) seeks $300M via common stock offering; SPY001 shows strong Phase 2 topline - Stock Titan
Spyre Therapeutics launches $300 million stock offering - Investing.com
Spyre’s SPY-001 induces better outcomes in ulcerative colitis - BioWorld News
Raymond James initiates Spyre stock with strong buy rating By Investing.com - Investing.com South Africa
Spyre Therapeutics' Trial Data Boosts Stock by 23% - Intellectia AI
Spyre Therapeutics announces proposed public offering of its common stock - marketscreener.com
Spyre Therapeutics Inc suspends and terminates ATM prospectus for at-the-market offering effective April 13, 2026SEC filing - marketscreener.com
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - The Manila Times
Spyre Therapeutics IncSuspends And Terminates ATM Prospectus For At-The-Market Offering Effective April 13, 2026SEC Filing - TradingView — Track All Markets
Small U.S. Stocks Close Up; Spyre Therapeutics Leads Increases - Moomoo
SYRE Stock Jumps As Stifel Hikes Price Target To $92 - timothysykes.com
Spyre moves to raise $300M, with room to expand the sale to $345M - Stock Titan
Spyre Therapeutics (NASDAQ: SYRE) ends ATM prospectus, reports $741M cash - Stock Titan
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):